SAT0302 Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression

BackgroundA relationship between systemic inflammation and increased cardiovascular risk is often postulated. Simple and affordable clinical predictors of increased cardiovascular risk in patients with autoimmune disease, however, are not yet available in the clinical practice.ObjectivesTo address t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.777-777
Hauptverfasser: Berti, A., Baragetti, A., Magnoni, M., Garlaschelli, K., Grigore, L., Berteotti, M., Scotti, I., Bozzolo, E., Ramirez, G.A., Manfredi, A.A., Ammirati, E., Catapano, A.L., Norata, G.D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 777
container_issue Suppl 2
container_start_page 777
container_title Annals of the rheumatic diseases
container_volume 75
creator Berti, A.
Baragetti, A.
Magnoni, M.
Garlaschelli, K.
Grigore, L.
Berteotti, M.
Scotti, I.
Bozzolo, E.
Ramirez, G.A.
Manfredi, A.A.
Ammirati, E.
Catapano, A.L.
Norata, G.D.
description BackgroundA relationship between systemic inflammation and increased cardiovascular risk is often postulated. Simple and affordable clinical predictors of increased cardiovascular risk in patients with autoimmune disease, however, are not yet available in the clinical practice.ObjectivesTo address the role of clinical, serological markers of disease activity, and of classical cardiovascular risk factors (CVRF) in predicting the carotid intima-media thickness (c-IMT) progression at 5 years (Δc-IMT) in patients with the prototypic autoimmune disease systemic lupus erythematosus (SLE).MethodsClinical and biochemical data including SLEDAI were collected at baseline and at five years of follow up from 50 patients with SLE and 50 age- and gender-matched healthy controls. C-IMT was also measured at baseline and at 5 years to evaluate progression.ResultsA higher SLEDAI score at baseline correlated with a faster Δc-IMT (0.007 (0.006) mm/year vs 0.003 (0.001) mm/year when compared to controls, P=0.026), irrespectively of the presence of CVRF and of the serological profile. Patients with higher SLEDAI score at baseline also experienced disease flares more frequently (p=0.037) than those with milder disease at baseline. Patients with a higher disease activity during follow up had also a faster Δc-IMT when compared to those with a persistently low disease activity (0.008 (0.004) mm/year vs -0.006 (0.004) mm/year, P=0.021). Elevated LDL-C levels were the only CVRF associated with disease flare-up; this might a consequence of the aggressive immunosuppressant therapy in those patients.ConclusionsPatient with SLE show an increased cardiovascular risk as estimated by the c-IMT. Disease activity and in particular disease flares accelerate the progression of the vascular damage.Disclosure of InterestNone declared
doi_str_mv 10.1136/annrheumdis-2016-eular.5698
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2441492600</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2441492600</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1550-e47d7f489ed7708e10c010884bae404716231939c0f0e1b761b38857ce58fa653</originalsourceid><addsrcrecordid>eNqVkc9O3DAQxi1UJLbAO0TiHDqTOI4tTqsVLUhbFYnlbDnJhHghyWI7RXvjwov2SeplOXBC4jR_9H0zmvkxdoZwjpiLH2YYXEdT31ifZoAipenRuPNCKHnAZsiFjG0B39gMAPKUK1Eese_er2MJEuWMdbfzFeSQ_Xt5ndfB_qXkdusD9bZOltNm8sml24aOehNGH6u592NtTSCfPNvQJQvjxmCb5HoItjfpb2qsSVadrR8G8j65ceO9i4kdhxN22JpHT6fv8Zjd_bxcLa7S5Z9f14v5Mq2wKCAlXjZly6WipixBEkINCFLyyhAHXqLIclS5qqEFwqoUWOVSFmVNhWyNKPJjdrafu3Hj00Q-6PU4uSGu1BnnyFUm4is-UaEClBxzpaLqYq-q3ei9o1ZvXDzTbTWC3gHQHwDoHQD9BkDvAES32Lurfv0l439LSZGV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901841399</pqid></control><display><type>article</type><title>SAT0302 Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression</title><source>BMJ Journals - NESLi2</source><creator>Berti, A. ; Baragetti, A. ; Magnoni, M. ; Garlaschelli, K. ; Grigore, L. ; Berteotti, M. ; Scotti, I. ; Bozzolo, E. ; Ramirez, G.A. ; Manfredi, A.A. ; Ammirati, E. ; Catapano, A.L. ; Norata, G.D.</creator><creatorcontrib>Berti, A. ; Baragetti, A. ; Magnoni, M. ; Garlaschelli, K. ; Grigore, L. ; Berteotti, M. ; Scotti, I. ; Bozzolo, E. ; Ramirez, G.A. ; Manfredi, A.A. ; Ammirati, E. ; Catapano, A.L. ; Norata, G.D.</creatorcontrib><description>BackgroundA relationship between systemic inflammation and increased cardiovascular risk is often postulated. Simple and affordable clinical predictors of increased cardiovascular risk in patients with autoimmune disease, however, are not yet available in the clinical practice.ObjectivesTo address the role of clinical, serological markers of disease activity, and of classical cardiovascular risk factors (CVRF) in predicting the carotid intima-media thickness (c-IMT) progression at 5 years (Δc-IMT) in patients with the prototypic autoimmune disease systemic lupus erythematosus (SLE).MethodsClinical and biochemical data including SLEDAI were collected at baseline and at five years of follow up from 50 patients with SLE and 50 age- and gender-matched healthy controls. C-IMT was also measured at baseline and at 5 years to evaluate progression.ResultsA higher SLEDAI score at baseline correlated with a faster Δc-IMT (0.007 (0.006) mm/year vs 0.003 (0.001) mm/year when compared to controls, P=0.026), irrespectively of the presence of CVRF and of the serological profile. Patients with higher SLEDAI score at baseline also experienced disease flares more frequently (p=0.037) than those with milder disease at baseline. Patients with a higher disease activity during follow up had also a faster Δc-IMT when compared to those with a persistently low disease activity (0.008 (0.004) mm/year vs -0.006 (0.004) mm/year, P=0.021). Elevated LDL-C levels were the only CVRF associated with disease flare-up; this might a consequence of the aggressive immunosuppressant therapy in those patients.ConclusionsPatient with SLE show an increased cardiovascular risk as estimated by the c-IMT. Disease activity and in particular disease flares accelerate the progression of the vascular damage.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.5698</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><subject>Autoimmune diseases ; Cardiovascular diseases ; Low density lipoprotein ; Lupus ; Risk factors ; Serology ; Systemic lupus erythematosus</subject><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.777-777</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2016 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://ard.bmj.com/content/75/Suppl_2/777.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://ard.bmj.com/content/75/Suppl_2/777.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Berti, A.</creatorcontrib><creatorcontrib>Baragetti, A.</creatorcontrib><creatorcontrib>Magnoni, M.</creatorcontrib><creatorcontrib>Garlaschelli, K.</creatorcontrib><creatorcontrib>Grigore, L.</creatorcontrib><creatorcontrib>Berteotti, M.</creatorcontrib><creatorcontrib>Scotti, I.</creatorcontrib><creatorcontrib>Bozzolo, E.</creatorcontrib><creatorcontrib>Ramirez, G.A.</creatorcontrib><creatorcontrib>Manfredi, A.A.</creatorcontrib><creatorcontrib>Ammirati, E.</creatorcontrib><creatorcontrib>Catapano, A.L.</creatorcontrib><creatorcontrib>Norata, G.D.</creatorcontrib><title>SAT0302 Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression</title><title>Annals of the rheumatic diseases</title><description>BackgroundA relationship between systemic inflammation and increased cardiovascular risk is often postulated. Simple and affordable clinical predictors of increased cardiovascular risk in patients with autoimmune disease, however, are not yet available in the clinical practice.ObjectivesTo address the role of clinical, serological markers of disease activity, and of classical cardiovascular risk factors (CVRF) in predicting the carotid intima-media thickness (c-IMT) progression at 5 years (Δc-IMT) in patients with the prototypic autoimmune disease systemic lupus erythematosus (SLE).MethodsClinical and biochemical data including SLEDAI were collected at baseline and at five years of follow up from 50 patients with SLE and 50 age- and gender-matched healthy controls. C-IMT was also measured at baseline and at 5 years to evaluate progression.ResultsA higher SLEDAI score at baseline correlated with a faster Δc-IMT (0.007 (0.006) mm/year vs 0.003 (0.001) mm/year when compared to controls, P=0.026), irrespectively of the presence of CVRF and of the serological profile. Patients with higher SLEDAI score at baseline also experienced disease flares more frequently (p=0.037) than those with milder disease at baseline. Patients with a higher disease activity during follow up had also a faster Δc-IMT when compared to those with a persistently low disease activity (0.008 (0.004) mm/year vs -0.006 (0.004) mm/year, P=0.021). Elevated LDL-C levels were the only CVRF associated with disease flare-up; this might a consequence of the aggressive immunosuppressant therapy in those patients.ConclusionsPatient with SLE show an increased cardiovascular risk as estimated by the c-IMT. Disease activity and in particular disease flares accelerate the progression of the vascular damage.Disclosure of InterestNone declared</description><subject>Autoimmune diseases</subject><subject>Cardiovascular diseases</subject><subject>Low density lipoprotein</subject><subject>Lupus</subject><subject>Risk factors</subject><subject>Serology</subject><subject>Systemic lupus erythematosus</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkc9O3DAQxi1UJLbAO0TiHDqTOI4tTqsVLUhbFYnlbDnJhHghyWI7RXvjwov2SeplOXBC4jR_9H0zmvkxdoZwjpiLH2YYXEdT31ifZoAipenRuPNCKHnAZsiFjG0B39gMAPKUK1Eese_er2MJEuWMdbfzFeSQ_Xt5ndfB_qXkdusD9bZOltNm8sml24aOehNGH6u592NtTSCfPNvQJQvjxmCb5HoItjfpb2qsSVadrR8G8j65ceO9i4kdhxN22JpHT6fv8Zjd_bxcLa7S5Z9f14v5Mq2wKCAlXjZly6WipixBEkINCFLyyhAHXqLIclS5qqEFwqoUWOVSFmVNhWyNKPJjdrafu3Hj00Q-6PU4uSGu1BnnyFUm4is-UaEClBxzpaLqYq-q3ei9o1ZvXDzTbTWC3gHQHwDoHQD9BkDvAES32Lurfv0l439LSZGV</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Berti, A.</creator><creator>Baragetti, A.</creator><creator>Magnoni, M.</creator><creator>Garlaschelli, K.</creator><creator>Grigore, L.</creator><creator>Berteotti, M.</creator><creator>Scotti, I.</creator><creator>Bozzolo, E.</creator><creator>Ramirez, G.A.</creator><creator>Manfredi, A.A.</creator><creator>Ammirati, E.</creator><creator>Catapano, A.L.</creator><creator>Norata, G.D.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>SAT0302 Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression</title><author>Berti, A. ; Baragetti, A. ; Magnoni, M. ; Garlaschelli, K. ; Grigore, L. ; Berteotti, M. ; Scotti, I. ; Bozzolo, E. ; Ramirez, G.A. ; Manfredi, A.A. ; Ammirati, E. ; Catapano, A.L. ; Norata, G.D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1550-e47d7f489ed7708e10c010884bae404716231939c0f0e1b761b38857ce58fa653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Autoimmune diseases</topic><topic>Cardiovascular diseases</topic><topic>Low density lipoprotein</topic><topic>Lupus</topic><topic>Risk factors</topic><topic>Serology</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berti, A.</creatorcontrib><creatorcontrib>Baragetti, A.</creatorcontrib><creatorcontrib>Magnoni, M.</creatorcontrib><creatorcontrib>Garlaschelli, K.</creatorcontrib><creatorcontrib>Grigore, L.</creatorcontrib><creatorcontrib>Berteotti, M.</creatorcontrib><creatorcontrib>Scotti, I.</creatorcontrib><creatorcontrib>Bozzolo, E.</creatorcontrib><creatorcontrib>Ramirez, G.A.</creatorcontrib><creatorcontrib>Manfredi, A.A.</creatorcontrib><creatorcontrib>Ammirati, E.</creatorcontrib><creatorcontrib>Catapano, A.L.</creatorcontrib><creatorcontrib>Norata, G.D.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berti, A.</au><au>Baragetti, A.</au><au>Magnoni, M.</au><au>Garlaschelli, K.</au><au>Grigore, L.</au><au>Berteotti, M.</au><au>Scotti, I.</au><au>Bozzolo, E.</au><au>Ramirez, G.A.</au><au>Manfredi, A.A.</au><au>Ammirati, E.</au><au>Catapano, A.L.</au><au>Norata, G.D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SAT0302 Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>777</spage><epage>777</epage><pages>777-777</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundA relationship between systemic inflammation and increased cardiovascular risk is often postulated. Simple and affordable clinical predictors of increased cardiovascular risk in patients with autoimmune disease, however, are not yet available in the clinical practice.ObjectivesTo address the role of clinical, serological markers of disease activity, and of classical cardiovascular risk factors (CVRF) in predicting the carotid intima-media thickness (c-IMT) progression at 5 years (Δc-IMT) in patients with the prototypic autoimmune disease systemic lupus erythematosus (SLE).MethodsClinical and biochemical data including SLEDAI were collected at baseline and at five years of follow up from 50 patients with SLE and 50 age- and gender-matched healthy controls. C-IMT was also measured at baseline and at 5 years to evaluate progression.ResultsA higher SLEDAI score at baseline correlated with a faster Δc-IMT (0.007 (0.006) mm/year vs 0.003 (0.001) mm/year when compared to controls, P=0.026), irrespectively of the presence of CVRF and of the serological profile. Patients with higher SLEDAI score at baseline also experienced disease flares more frequently (p=0.037) than those with milder disease at baseline. Patients with a higher disease activity during follow up had also a faster Δc-IMT when compared to those with a persistently low disease activity (0.008 (0.004) mm/year vs -0.006 (0.004) mm/year, P=0.021). Elevated LDL-C levels were the only CVRF associated with disease flare-up; this might a consequence of the aggressive immunosuppressant therapy in those patients.ConclusionsPatient with SLE show an increased cardiovascular risk as estimated by the c-IMT. Disease activity and in particular disease flares accelerate the progression of the vascular damage.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2016-eular.5698</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.777-777
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_2441492600
source BMJ Journals - NESLi2
subjects Autoimmune diseases
Cardiovascular diseases
Low density lipoprotein
Lupus
Risk factors
Serology
Systemic lupus erythematosus
title SAT0302 Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T20%3A14%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SAT0302%E2%80%85Active%20Systemic%20Lupus%20Erythematosus%20Associates%20with%20Carotid%20Intima-Media%20Thickness%20Progression&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Berti,%20A.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=777&rft.epage=777&rft.pages=777-777&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.5698&rft_dat=%3Cproquest_cross%3E2441492600%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901841399&rft_id=info:pmid/&rfr_iscdi=true